# Collagen Joint Pain Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/collagen-joint-pain-randomized-trial-evidence-review
Category: evidence-review
Summary: Collagen Joint Pain Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are ra
Last reviewed: 2026-05-20
Reviewed by: Migaku Evidence Review
# Collagen Joint Pain Randomized Trial: What the Evidence Says

## Quick Answer

Collagen Joint Pain Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Efficacy and tolerability of native (undenatured) type II collagen supplementation for joint health in healthy volunteers: a randomized double-blind placebo-controlled study | randomized trial | 2 | 2026-03-06 | 10.1186/s12937-026-01302-0 |
| Managing Osteoarthritis Pain in Underrepresented Populations: Insights from Mexico and Latin America | narrative review | 3 | 2026-03-21 | 10.3390/jcm15062396 |

## What The Sources Report

- In 2020, OA was a top-ten leading cause of years lived with disability (YLD), and its prevalence is expected to rise as a result of the increase in life expectancy, becoming a major socioeconomic and public health issue. [Möller Ingrid (2026); evidence level 2]
- The most recent reports have indicated that worldwide prevalence rates have dramatically increased by 113.25% over the past 20 years. [Vázquez-Del Mercado Mónica (2026); evidence level 3]
- The highest prevalence rate has been observed in Latin America, which increased by 203.56% from 1990 to 2019. [Vázquez-Del Mercado Mónica (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For collagen joint pain randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Möller Ingrid (2026). Efficacy and tolerability of native (undenatured) type II collagen supplementation for joint health in healthy volunteers: a randomized double-blind placebo-controlled study. DOI: 10.1186/s12937-026-01302-0. PMCID: PMC13077837. PMID: 41787523. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13077837/
- Vázquez-Del Mercado Mónica (2026). Managing Osteoarthritis Pain in Underrepresented Populations: Insights from Mexico and Latin America. DOI: 10.3390/jcm15062396. PMCID: PMC13026629. PMID: 41899318. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13026629/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.